NVNO News & Events

enVVeno Medical announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe transcatheter replacement venous valve system for the treatment of venous disease. The issued patent covers key components of the enVVe system, including the enVVe valve, valve support frame, crimping system, and delivery system, as well as methods for use in treating patients with deep venous insufficiency. The enVVe system is the transcatheter evolution of the clinically proven surgical device, designed to restore proper one-way blood flow in the deep veins of the leg.

The Company anticipates that its cash burn rate may increase to approximately $4 million to $5 million per quarter in 2026 as it prepares for and initiates the TAVVE pivotal study.

"With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the Company towards multiple near-term and long-term milestones," said Robert Berman, Chief Executive Officer of enVVeno Medical.